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Discovery, Semisynthesis, 
Antiparasitic and Cytotoxic 
Evaluation of 14-Membered 
Resorcylic Acid Lactones and Their 
Derivatives
Xue-Qing Zhang1,2, Carmenza Spadafora  3, Laura M. Pineda3, Michelle G. Ng3, Ji-Hong 
Sun1,2, Wei Wang1,2, Chang-Yun Wang1,2, Yu-Cheng Gu4 & Chang-Lun Shao1,2
Ten antifouling 14-membered resorcylic acid lactones 1–10 were isolated previously with low or trace 
natural abundance from the zoanthid-derived Cochliobolus lunatus fungus. Further optimization of 
fermentation conditions led to the isolation of two major natural compounds 7 and 8 with multi-gram 
quantities. By one or two steps, we semisynthesized the six trace natural compounds 1–6 and a series 
of derivatives 11–27 of compounds 7 and 8 with high yields (65–95%). Compounds 11–13 showed strong 
antiplasmodial activity against Plasmodium falciparum with IC50 values of 1.84, 8.36, and 6.95 μM, 
respectively. Very importantly, 11 and 12 were non-toxic with very safety and high therapeutic indices 
(CC50/IC50 > 180), and thus representing potential promising leads for antiplasmodial drug discovery. 
Furthermore, 11 was the only compound showed obvious antileishmanial activity against Leishmania 
donovani with an IC50 value of 9.22 μM. Compounds 11 and 12 showed the values of IC50 at 11.9 and 
17.2 μM against neglected Chagas’ disease causing Trypanosoma cruzi, respectively.
Protozoan infections such as malaria, leishmaniasis, and Chagas’ disease remain a major threat to public health 
especially in the tropical regions of the world. Malaria is a life-threatening mosquito-borne infectious disease 
caused by a parasite of the genus Plasmodium. According to the World Health Organization, there are 212 million 
new cases of malaria with 429,000 deaths in 2015. Malaria is a serious problem especially in Africa, where it is 
responsible for most global malaria cases (90%)1. Leishmaniasis is a debilitating and devastating disease caused 
by protozoan parasites of the genus Leishmania, which is endemic in 98 countries, with 20,000–30,000 deaths 
and 0.7–1.0 million new cases annually2. Chagas’ disease or American trypanosomiasis is caused by the parasite 
Trypanosoma cruzi and is responsible for about 5.7 million people infected with the parasite and 7,000 deaths 
per year3,4. Current drugs used for the treatment of these diseases are effective, but resistance and side effects, in 
some cases serious, have been reported for all the current therapeutic agents5–8. There is therefore an urgent need 
to develop new antimalarial, antileishmanial, and antitrypanosomal agents that act on new targets with novel 
modes of action.
Fungi have been proven to be a rich source of structurally diverse and biologically active secondary metab-
olites that are of considerable synthetic interest and dramatic significance as promising leads for drug discovery 
and development9,10. 14-Membered resorcylic acid lactones (RALs) constitute a class of fungal polyketide metab-
olites which exhibit a wide range of biological properties including antimalarial11,12, cytotoxic13, antiparasitic, 
antiviral14, and kinase inhibitory15,16 activities. Paecilomycins E and F, with potent antiplasmodial activity against 
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P. falciparum lines 3D7 (IC50: 20 nM and 1.1 μM) and Dd2 (IC50: 8.8 μM and 1.7 μM, respectively), were isolated 
from a Paecilomyces fungus11,12. Hypothemycin and aigialomycin D that exhibited antimalarial activity against 
P. falciparum lines K1 with IC50 values of 2.2 and 6.6 μg/mL respectively and cytotoxicity, were isolated from 
Aigialus parvus13. In our previous studies, cochliomycins A, C–F (1–5), and several analogues (6–10) have been 
isolated with low or trace yields from the fungus C. lunatus (M351)17 and C. lunatus (TA26-46)18. In view of their 
potentially biological applications, cochliomycins have attracted the attention of academic groups to synthesize 
these compounds. The most challenging part of their syntheses was the assembly of the macrolide ring and a sig-
nificant range of techniques with complicated procedures have been tried and improved19–25. For example, coch-
liomycin A was firstly synthesized with 22 steps (6.5% overall yields) employing stereo-selective Keck allylation, 
Juliae–Kocienski olefination and a late-stage RCM reaction as the key steps19. Meanwhile, the scarce availability 
of the natural products including time-consuming isolation protocols has also prompted our study of alternative 
sources of these materials for additional studies.
Up to now, total syntheses of cochliomycins A–C have been accomplished extensively by Nanda’s group19,24, 
Du’s group20,21, Srihari’s group23, and Banwell’s group22,25. Cochliomycin A (1) was firstly synthesized in overall 
yield of 6.5% in 201219, and then was stereo-selectively synthesized by Wang et al. with 16 steps and only mg scale 
(23.0 mg)20. Cochliomycin B has been synthesized in 4.8% overall yields21 and the latest progress in the modular 
total syntheses of 1 (36.8 mg) and cochliomycin B (58.0 mg) were reported with 18 steps22. Cochliomycins A–C 
were in close resemblance to antiplasmodial paecilomycins E and F structurally, and cochliomycin C (2) is a chlo-
rinated derivative of paecilomycin F on aromatic ring at C5 carbon. Total syntheses of paecilomycins E and F were 
also accomplished and reported during the period 2012–201626–30. Very recently, cochliomycin C (2) and paecilo-
mycin F were synthesized successively by Srihari’s group23 with 16 steps, Nanda’s group24 with 12 steps in overall 
yield of 14.1%, and Banwell’s group25 with 11 steps. There is no report on total syntheses of compounds 3–6. 
Alternatively, semisynthetic strategy could provide an efficient and economical route to obtain natural products 
for further investigation of their pharmacological activities.
In this study, further optimization of the fermentation conditions of C. lunatus resulted in multi-gram quan-
tities of compounds 7 and 8, and the one or two-step semisyntheses of natural compounds 1–6 and a series of 
derivatives 11–27 with high yields were reported (Fig. 1). The antiplasmodial, antileishmanial, antitrypanosomal, 
and cytotoxic activities of these compounds were evaluated in vitro. The preliminary structure-activity relation-
ships were discussed.
Results and Discussion
Progress of the optimization of fermentation. The fungal strain C. lunatus was cultured in a 500 mL 
flask containing 200 mL liquid medium and incubated at 28 °C for 7 days on a rotary shaker at 120 rpm. The result 
Figure 1. Chemical structures of natural compounds 1–10 and their derivatives 11–27.
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of analysis showed that 7 and 8 are two predominant products in oligotrophic liquid medium (soluble starch 
10 g/L, tryptone 1 g/L, 3% salinity). Then, the medium was selected as the basic medium for further optimiza-
tion. The level of all the single factors including carbon source, nitrogen source, salinity, pH, inoculum size, and 
cultural time were studied. Subsequently, orthogonal test was carried out to approach the optimum point. All 
experiments were carried out in triplicate and the yields of 7 and 8 were calculated as the average values of three 
independent experiments. The fermented liquid medium was extracted with 200 mL ethyl acetate for each flask 
three times. The yield of 8 was 155.4 mg/L (soluble starch 10 g/L, NaNO3 5 g/L, NaOAc 1 g/L, 1% salinity, 10% 
inoculum size, adjusting initial pH value to 6 with 10% HCl/NaOH, Medium I). The yield of 7 reached 137.8 mg/L 
(soluble starch 10 g/L, NaNO3 5 g/L, 0.1% salinity, 15% inoculum size, adjusting initial pH value to 6 with 10% 
HCl/NaOH, Medium II) (Fig. 2). This supplied with a feasible method to obtain multi-gram quantities of 7 and 
8 by fermentation in the laboratory. The advantages of the fermentation method were low cost, time saving, and 
easy separation by recrystallization. The structures of 7 and 8 were determined by comparing the NMR and MS 
spectroscopic data with that reported in literature31,32.
Semisynthesis. Compounds 1–6 and 11–27 were designed and synthesized through one or two-step semi-
synthetic reaction with high yields ranging from 65–95% from 7 and 8 (Fig. 1). The structures of new derivatives 
12, 14–19, 21–22, 24, and 27 were identified by extensive spectroscopic methods including HRESIMS, 1H NMR, 
and 13C NMR. Compound 1 was prepared in yield of 95% through one-step acetonide reaction from 8. Other 
acetonide derivatives (11, 17, 18, 20, 23, 25, and 26) were also prepared with the same yields. Chlorination of 
compound 8 with sulfuryl chloride33 followed by selective reduction with 10% Pd-C under H2 atmosphere led to 
the natural compound 2 (68%, yield). Acylation reaction was carried out by reaction of anhydride with the cor-
responding materials (1–3, and 6–8) in high yields (85–95%). In order to prepare 6, oxidation of the allyl alcohol 
8 was examined under various oxidation conditions (PCC, PDC, MnO2, DMP, and IBX). However, only DMP 
and IBX enabled the selective oxidation of the allyl alcohol to give 6 in 65% and 35% yields, respectively (Fig. 3). 
Interestingly, a fortuitous observation revealed that 6 can slowly proceed in chemical conversion to 3–5 in the pro-
cess of silica gel column separation. Compounds 3–6 are diastereomers differing from each other by the absolute 
configurations of the 4′, 5′-diol chiral centers. The proportions of compounds 3–6 were in dynamic equilibrium, 
and the final ratios of 3–6 were approximately 8: 2: 5: 6 (Fig. 4). Further study revealed that a subtle chemical 
conversion of 6 to 3–5 was observed in protic solvents (MeOH, EtOH, and MeOH-d4, except for H2O) in the sta-
tionary state within a week, and similar interconversion of 4 and 5 were also observed under the same conditions, 
while compound 3 was found to be quite stable (Fig. 5). However, compounds 4–6 were found to be stable in 
Figure 2. HPLC profiles for the EtOAc extract of metabolites in the media Medium I and Medium II.
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Figure 3. Example of one or two-step semisyntheses of compounds 1, 2, 6, 13, and 16.
Figure 4. Semisynthesis of compound 6 and chemical conversion of 6 to 3–5.
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aprotic solvents (EtOAc, CH3CN, acetone, and CH2Cl2). Compounds 4–6 were unstable because of the existence 
of trans-enone moieties and the absolute configurations of the 4′, 5′-diol groups, causing chemical conversions 
under the condition of protic solvent, such as intramolecular hetero Michael addition34 and carbon migration of 
hemiacetal35. This conversion played a vital role in obtaining compounds 3–5 for further biological study.
Antiplasmodial activity. Results for the in vitro antiplasmodial activity of all of the compounds were shown 
in Table 1. Compounds 11–13 and 26 exhibited strong antiplasmodial activity with the IC50 values of 1.84, 8.36, 
6.95, and 8.95 μM, respectively. It should be pointed that the introduction of the acetoxy groups in compounds 
1 and 8 appreciably change the activity, indicating that adding the acetoxy groups has a positive effect on the 
antiplasmodial activity. The acetonide functionality in 11 improved the IC50 value approximately 4-fold over that 
of 13 with the acetoxy groups at C5′-C6′. This suggests that the acetonide functionality might contribute to the 
antiplasmodial activity. However, the introduction of the chlorine atom at C5 in 2 and 16–19 was all found to be 
inactive, indicating that the chlorine atom has a negative effect on the antiplasmodial activity (Fig. 6).
Antileishmanial activity. Antileishmanial activity of all of the compounds was tested in vitro against L. 
donovani and were also shown in Table 1. For the enone RALs, compounds 3, 6, 7, 20–22, 26, and 27 displayed 
obvious antileishmanial activity with IC50 values ranging from 1.24 μM to 9.11 μM. Additionally, antiplasmodial 
compound 11 also showed antileishmanial activity with an IC50 value of 9.22 μM.
Antitrypanosomal activity. The bioassays against T. cruzi of all 27 molecules showed little activity against 
this parasite in initial screenings at 10 μg/mL, except in the cases when the compound was also discovered to be 
toxic (data not shown). However, compounds 11 and 12 showed IC50 values of 11.9 and 17.2 μM, respectively, 
with selectivity indexes of 28 and 88, making 12 a good candidate for in vivo studies.
Toxicity. It should be emphasized that toxicity is a major concern of drug discovery and development. The 
above active compounds were evaluated for in vitro toxicity against a mammalian kidney cell line (Vero). The 
selectivity index (SI) was used as the evaluation parameter of drug potential of the test samples by comparing 
the toxicity on the Vero cell line (CC50) and the selective inhibitory effect on P. falciparum, L. donovani or T. 
cruzi (IC50) calculated here as CC50/IC50. Compounds 11–13 and 15 were found to be non-toxic and showed 
Figure 5. Chemical interconversion of compounds 3–6 in MeOH.
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encouraging therapeutic indices, which were far greater than the value requested by the Medicine for Malaria 
Venture (SI > 10). Specially, antiplasmodial compounds 11 and 12 showed pronounced selectivity indices 
(SI > 180), and thus represent potentially promising antiplasmodial leads for further development. Compounds 
12 and 13, where 12, with a 2-OH group, displayed 3-fold higher therapeutic ratio and equivalent or stronger 
activities than compound 13, indicating that 2-OH is an important functionality for reducing the toxicity. For the 
enone RALs, most of them had high antileishmanial efficacy but poor therapeutic indices, indicating that the cis 
or trans-functionality has a positive contribution to toxicity, and that the antileishmanial activity of these com-








IC50 (μM) SI IC50 (μM) SI IC50 (μM) SI CC50 (μM)
1 30.7 3 I — I — 96.0
2 I — I — I — nt
3 I — 9.11 — I — nt
4 I — 15.2 — I — nt
5 I — I — I — nt
6 14.9 <1 1.93 2 nt — 3.20
7 11.0 <1 2.21 <1 nt — <1
8 I — I — I — 227.1
9 I — I — I — 131.0
10 I — I — I — 273.8
11 1.84 184 9.22 37 11.9 28 338.7
12 8.36 182 15.7 97 17.2 88 1520.5
13 6.95 61 I — I — 426.6
14 I — I — I — nt
15 22.2 71 I — I — 1567.8
16 I — I — I — 260.0
17 I — I — I — 143.1
18 I — I — I — 101.9
19 I — I — I — nt
20 I — 6.46 <1 nt — <1
21 I — 3.69 2 nt — 5.80
22 20.1 <1 3.03 4 6.31 2 11.5
23 I — I — I — nt
24 I — 12.1 <1 nt — 3.20
25 I — I — I — nt
26 8.95 <1 1.24 <1 nt — <1
27 I — 3.14 <1 nt — <1
Table 1. Antiplasmodial, antileishmanial, antitrypanosomal, and toxic activities of compounds 1–27. SI: 
Selectivity Index (CC50/IC50); I: Inactive; nt: Not tested.
Figure 6. The structure-activity relationships of RALs.
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Cytotoxic activity. All of the compounds were also evaluated for their cytotoxic properties against six 
human cancer cell lines (lung carcinoma epithelian (A549), colon carcinoma (HCT-116), pancreatic carcinoma 
(BXPC-3), breast cancer (MCF-7), cervical epithelium (HeLa), and erythroleukemic (K562)) and a human umbil-
ical vein endothelial cell (HUVEC) line (Table 2). Compounds 3, 6, 7, 20, 21, 23, 26, and 27 with the enone 
functionality exhibited selectively cytotoxicity against the above cell lines with IC50 values less than 10 μM. This 
further confirmed that the enone functionality was related to the toxicity.
Conclusion
In summary, the natural products 1–6 and a group of derivatives 11–27 were semisynthesized with multi-gram 
scales of 7 and 8 by one or two steps with high yields. This semisynthetic route provided a convenient source 
of these RALs for further potentially biological applications. Compounds 11–13 showed strong antiplasmodial 
activity against P. falciparum, of which 11 and 12 were discovered to be promising non-toxic antiparasitic can-
didates. The structure-activity relationship analysis indicated that the acetoxy and acetonide groups are required 
for antiplasmodial activity, while the introduction of chlorine atom at C-5 is not necessary to the activity. 
Additionally, enone group can lead to an obvious toxicity and a comparatively lower therapeutic ratio, but 2-OH 
is critical for reducing toxicity. Further studies of selected compounds 11–13 on assessing their in vivo activities 
and a systematic optimization based upon these identified promising chemical leads are in progress and will be 
reported in due course.
Methods
General experimental procedures. NMR spectra were recorded with TMS as internal standard on an 
Agilent DD2 NMR spectrometer (500 and 125 MHz for 1H and 13C NMR, respectively). HRESIMS and ESIMS 
spectra were obtained from a Micromass Q-TOF spectrometer. Optical rotations were measured on a JASCO 
P-1020 digital polarimeter. Silica gel (Qing Dao Hai Yang Chemical Group Co.; 200–300 mesh), and Sephadex 
LH-20 (Amersham Biosciences) were used for column chromatography (CC). TLC silica gel plates (Yan Tai Zi Fu 
Chemical Group Co.; G60, F-254) were used for thin-layer chromatography. Semipreparative HPLC was carried 
out on a Waters 1525 system using a semipreparative C18 (Kromasil, 5 μm, 10 × 250 mm) column equipped with 
a Waters 2996 photodiode array detector, at a flow rate of 2.0 mL/min.
No.
Cytotoxicity IC50 (μM)
HCT-116 BXPC-3 HeLa MCF-7 A-549 K562 HUVEC
1 I I I I I I nt
2 I I I I I I nt
3 I I 7.18 I I I nt
4 I I I I I I nt
5 I I I I I I nt
6 I 8.47 I I I I 8.59
7 1.09 5.07 I I I I I
8 I I I I I I I
9 I I I I I I nt
10 I I I I I I nt
11 I I I I I I I
12 I I I I I I I
13 I I I I I I I
14 I I I I I I nt
15 nt nt nt nt nt nt nt
16 I I I I I I nt
17 I I I I I I no
18 I I I I I I no
19 I I I I I I no
20 I I 7.21 I I I 9.78
21 I I 6.95 I I I 4.52
22 nt nt nt nt nt nt nt
23 3.51 nt 6.59 nt 9.75 nt 7.51
24 I nt I nt I nt I
25 I I I I I I I
26 9.16 7.22 4.02 I I I 4.81
27 2.83 nt 3.85 nt 7.30 nt 5.90
Adriamycin 0.21 0.033 0.60 0.86 0.16 0.25 —
Table 2. Cytotoxic activity of compounds 1–27. I: Inactive; nt: Not tested.
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Fungal material. The fungal strain C. lunatus (CHNSCLM-0009) was isolated from the inner part of the 
zoanthid Palythoa haddoni, collected by hand from the South China Sea in April 2010. The fungus was identified 
as C. lunatus on the basis of 16 S rRNA gene analysis with the access code JF819163.
Fermentation, extraction, and isolation. The fungal strain was cultivated in 10 L of optimal liquid 
medium (Medium I and Medium II, respectively) at 28 °C for 7 days on a rotary shaker at 120 rpm. Then the 
culture was filtered to separate the culture broth from the mycelia. The culture broth was extracted with an equal 
volume of EtOAc. The combined EtOAc solution was evaporated to dryness under a vacuum to give an EtOAc 
extract. The EtOAc extract (4.22 g) was subjected to Sephadex LH-20 column chromatography (120.0 cm × 3.0 cm 
i.d.) with 1.5 L petroleum ether/CH2Cl2/MeOH (2:1:1, v/v/v), and then recrystallization with MeOH/CH2Cl2 to 
obtain 8 (1.71 g) and 7 (1.35 g).
Semisynthesis of cochliomycin C (2). SO2Cl2 (0.045 mL, 0.36 mmol) in CH2Cl2 (5.0 mL) was added to the 
solution of zeaenol (8) (90.0 mg, 0.25 mmol) in dry CH2Cl2 (25.0 mL) at 0 °C. After 1 h the reaction was quenched 
by the addition of 25.0 mL of 5% aqueous NH4Cl solution and diluted with CH2Cl2 (30.0 mL). The organic layer 
was separated and the organic solvents were removed under a vacuum. The residue as purified by silica gel col-
umn chromatography (EtOAc/petroleum, 1:1, v/v) to give 16 as a white solid (87.5 mg, 90%). The resulting 16 
(50.0 mg, 0.13 mmol) was then treated with 10% Pd-C (5.0 mg) in MeOH (35.0 mL) under H2 atmosphere, and the 
solution was stirred for 1.5 h at room temperature. The mixture was filtered and concentrated under a vacuum. 
The residue was purified by semipreparative HPLC to give 2 as a white solid (37.4 mg, 75%), the spectroscopic 
data of which were consistent with that reported in literature17.
Allyl alcohol-oxidation of 8 to yield 3–6. Pyridine (24 µL, 0.25 mmol) was added to a solution of 8 
(30 mg, 0.082 mmol) in CH2Cl2 (20 mL). After the solution was cooled to 0 °C, the Dess-Martin periodinane 
(45 mg, 0.11 mmol) and NaHCO3 (14 mg, 0.16 mmol) were added as a solid. The mixture was stirred at 0 °C for 
30 min, and then was allowed to stir at room temperature for 2 h. The mixture was diluted with Et2O (30 mL), 1 M 
aqueous Na2S2O3 (15 mL), and 5% aqueous NaHCO3 (15 mL) were added. This biphasic mixture was stirred for 
0.5 h and the organic layer was separated and concentrated to dryness in vacuo. The crude mixture was immedi-
ately purified by Sephadex LH-20 CC eluted with petroleum ether/CH2Cl2/MeOH (2:1:1, v/v/v) to obtain pure 
compound 6 (19.5 mg). The obtained crude mixture was purified by silica gel CC eluted with EtOAc-petroleum 
(1:1), and then subjected to semipreparative HPLC to give the compounds 3 (6.8 mg), 4 (1.7 mg), 5 (4.3 mg), and 
6 (5.2 mg), respectively. The structures of 3–6 were determined by comparing NMR data and MS spectrum with 
the literature18.
Antiplasmodial assay. Activity against the causative agent of malaria was performed by culturing human 
erythrocytes and infecting them with P. falciparum, as described by Trager and Jensen36. Briefly, the W2 
(Chloroquine resistant) and 3D7 (Chloroquine sensitive) strains of P. falciparum were cultured in RPMI 1640 
medium (Sigma-Aldrich, USA) supplemented with 10% human serum (from O+ blood) at a hematocrit of 2% 
erythrocytes (O+) at 37 °C in a gas mixture of 5% CO2, 5% O2, and 90% N2. Parasites were synchronized by a 
temperature cycling technique as described by Almanza et al.37 Malaria bioassays were performed following the 
procedure of Corbett et al., which used Pico-Green to assess parasite growth inhibition by drugs and used chlo-
roquine as positive control, with an IC50 of 32.9 nM38.
Antileishmanial assay. The anti-leishmania activity was evaluated following the protocol described by 
Calderon et al.39, using the fluorescent DNA intercalator PicoGreen (Invitrogen, USA). The species responsible 
for visceral leishmaniasis, L. donovani, was used for the assays. Amphotericin B was used as the positive control 
and had an IC50 of 76.3 nM40.
Antitrypanosomal assay. The antitrypanosomal test used the methods recommended in Romanha et al. 
for screening against this parasite with benznidazole as the control drug, with an IC50 of 3.85 μM41. Briefly, the 
expression of the reporter gene for beta-galactosidase (β-Gal) in the Tulahuen clone C4 of T. cruzi is assessed by 
colorimetry at 570 nm, which correlates with the parasite growth42. Assays were performed on the intracellular 
amastigote form of the parasite infecting African green monkey kidney (Vero) cells, incubated for 120 h at 37 °C 
with 5% CO2.
SRB and MTT assays. The cytotoxicity against HCT-116, BXPC-3, HeLa, MCF-7, A-549, and HUVEC cell 
lines was evaluated using the SRB method43. The cytotoxicity against K562 and Vero cell lines was evaluated using 
the MTT method44. Adriamycin was used as a positive control. All cells were cultivated in T-75 flasks contain-
ing 10% Fetal Bovine Serum (FBS), Dulbeco’s Modified Eagle Medium (DMEM) with 2 mM L-glutamine, and 
1% penicillin-streptomycin at 37 °C in a humidified atmosphere with 5% CO2. For SRB assay, cells in their log 
phase of growth were seeded into 96 well micro plates (4 × 104 cells per well) and followed by treating with test 
samples at 10 μM or DMSO. After incubation at 37 °C for 72 h, the cells were fixed with the cold 20% (w/v) TCA 
for 2 h and stained with Sulforhodamine B (SRB) dye for 0.5 h. The protein-bound dye is dissolved in Tris base 
solution for OD determination at 540 nm on an ELISA Plate Reader. For MTT assay, cells (5 × 103 cells per well) 
were plated in 96 well micro plates. After cell attachment overnight, new medium containing test compounds or 
DMSO was added. The plate was incubated for 48 h at 37 °C and incubated with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) for additional 2–4 hours. The assay plate was then read at 490 nm on an 
ELISA Plate Reader. The data were obtained from experiments carried out in triplicate.
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